For three years semaglutide was the standard. Wegovy\u00ae hit the market in 2021 with the STEP 1 trial showing 14.9% mean weight loss at 68 weeks. Nothing approved had ever come close. Then tirzepatide (Mounjaro\u00ae for diabetes, Zepbound\u00ae for obesity) arrived and posted 20.9% in SURMOUNT-1. The market had a new leader, but not a clear winner for every patient.<\/p>\n
In 2024 the SURMOUNT-5 trial answered the question directly. It pitted semaglutide 2.4 mg against tirzepatide 15 mg in a head-to-head obesity trial. Tirzepatide won on weight loss (20.2% vs 13.7%). The verdict on raw weight loss is settled. But weight loss isn’t the only thing that matters.<\/p>\n
This guide compares them across every dimension that matters in 2026: efficacy, side effects, cardiovascular outcomes, kidney protection, diabetes control, cost, accessibility, and the practical experience of being on each drug.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Semaglutide is a single agonist of the GLP-1 receptor.<\/strong> It mimics the gut hormone glucagon-like peptide 1, slowing gastric emptying, increasing satiety, improving insulin secretion in response to glucose, and reducing food reward signaling. The drug is given as a weekly subcutaneous injection.<\/p>\n Quick Answer: SURMOUNT-5 (Aronne et al. 2024 NEJM) showed tirzepatide produced 20.2% weight loss vs semaglutide’s 13.7% in head-to-head<\/p>\n Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The combined action appears to produce greater weight loss, possibly through GIP-mediated effects on fat metabolism and additional brain signaling pathways.<\/p>\n The clinical effect is similar in kind, different in magnitude. Both drugs reduce appetite, slow gastric emptying, and improve glucose handling. Tirzepatide tends to produce these effects more strongly.<\/p>\n Tirzepatide wins on raw weight loss.<\/strong> SURMOUNT-5 (Aronne et al. 2024 NEJM) tested both drugs head-to-head in 751 adults with obesity over 72 weeks. Mean weight loss was 20.2% on tirzepatide 15 mg vs 13.7% on semaglutide 2.4 mg. The proportion of patients losing at least 25% of body weight was 31.6% on tirzepatide vs 16.1% on semaglutide.<\/p>\n The trial isolated the drug effect from individual variation by randomizing patients to one or the other. The 6.5 percentage point gap was statistically and clinically significant.<\/p>\n In their separate major trials, the gap was similar: STEP 1 (Wilding et al. 2021 NEJM) showed semaglutide producing 14.9% at 68 weeks, and SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed tirzepatide producing 20.9% at 72 weeks.<\/p>\n For pure weight loss outcome, tirzepatide is the higher-performing drug.<\/p>\n Semaglutide is currently ahead here.<\/strong> The SELECT trial (Lincoff et al. 2023 NEJM) tested semaglutide 2.4 mg in 17,604 adults with overweight or obesity plus established cardiovascular disease over a mean 3.3 years. Major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) were reduced by 20%. This was the first cardiovascular outcomes trial for a weight loss-dose GLP-1 in a non-diabetic population.<\/p>\n Tirzepatide doesn’t yet have an equivalent obesity-population cardiovascular outcome trial. The SURPASS-CVOT trial, which is ongoing, will compare tirzepatide vs dulaglutide on cardiovascular outcomes in adults with type 2 diabetes. Results are expected to read out in 2025.<\/p>\n Until SURPASS-CVOT and similar trials report, semaglutide has the stronger CV evidence base. For patients with established cardiovascular disease, this can be a meaningful tiebreaker.<\/p>\n Semaglutide is ahead here too.<\/strong> The FLOW trial (Perkovic et al. 2024 NEJM) tested semaglutide 1 mg in 3,533 patients with type 2 diabetes and chronic kidney disease. Major kidney outcomes plus cardiovascular death were reduced by 24% over 3.4 years.<\/p>\n Tirzepatide doesn’t have a published large kidney outcome trial yet. Trials are in progress.<\/p>\n For patients with diabetic kidney disease, semaglutide has the stronger evidence base for kidney protection.<\/p>\n Tirzepatide is ahead here.<\/strong> SURMOUNT-OSA (Malhotra et al. 2024 NEJM) tested tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. Patients on tirzepatide had a 25 to 30 events\/hour reduction in apnea-hypopnea index versus much smaller changes on placebo. The FDA approved tirzepatide for OSA in December 2024, the first medication approved for this indication.<\/p>\n Semaglutide hasn’t had a comparable OSA outcome trial published. For patients whose primary driver is moderate-to-severe OSA, tirzepatide now has the only on-label indication.<\/p>\n Both drugs are highly effective for type 2 diabetes.<\/strong> Tirzepatide produces slightly larger A1C reductions on average. The SURPASS program showed A1C reductions of 1.9% to 2.6% on tirzepatide at the higher doses. The SUSTAIN program showed A1C reductions of 1.0% to 1.8% on semaglutide at typical diabetes doses.<\/p>\n For patients with type 2 diabetes who also want weight loss, tirzepatide has a small edge on both ends. For patients with diabetes plus established kidney disease, semaglutide’s FLOW data is the stronger evidence base.<\/p>\n Key Takeaway: Semaglutide has kidney outcome data (FLOW, 24% reduction in kidney\/CV death) tirzepatide doesn’t yet have<\/p>\n Both drugs have a similar GI side effect profile: nausea, vomiting, diarrhea, and constipation are the most common adverse events.<\/strong> In SURMOUNT-5 head-to-head, GI side effect rates were similar between the two. Discontinuation for adverse events was 6.1% on tirzepatide and 8.0% on semaglutide.<\/p>\n Tirzepatide produces slightly more constipation in some real-world reports; semaglutide produces slightly more nausea on initiation. Individual response varies enormously. Some patients tolerate one but not the other.<\/p>\n Both have boxed warnings for medullary thyroid C-cell tumor risk based on rodent data, with no clear human signal in 15+ years of GLP-1 use. Both can cause gallbladder issues during rapid weight loss. Both have rare reports of pancreatitis.<\/p>\n Brand prices in 2026: Wegovy (semaglutide for obesity) lists at approximately $1,349\/month.<\/strong> Zepbound (tirzepatide for obesity) lists at approximately $1,086\/month. Ozempic\u00ae and Mounjaro (the diabetes brands) list at similar prices.<\/p>\n Eli Lilly’s LillyDirect cash program offers Zepbound vials at around $349 to $499\/month for single-dose vials. Novo Nordisk’s NovoCare offers similar direct pricing on Wegovy at around $499\/month.<\/p>\n Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx typically run $200 to $500\/month, with tirzepatide usually priced slightly higher than semaglutide.<\/p>\n The price gap between the two is small at compounded pricing. At brand pricing, Zepbound is slightly cheaper.<\/p>\n Both require dose escalation to manage GI side effects.<\/strong> Semaglutide titration: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, stepping up every 4 weeks for a total of 16 weeks to reach maintenance.<\/p>\n Tirzepatide titration: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, stepping up every 4 weeks for a total of 20 weeks to reach maintenance.<\/p>\n Tirzepatide takes 4 more weeks to reach top dose. Many patients on tirzepatide get strong weight loss at lower doses (5 or 7.5 mg) and don’t need to push to 15 mg.<\/p>\n Both are designed for chronic, indefinite use.<\/strong> The trial data show that stopping either leads to weight regain (STEP 4 for semaglutide, SURMOUNT-4 for tirzepatide). SURMOUNT-4 (Aronne et al. 2024 JAMA) demonstrated this for tirzepatide: patients switched to placebo at week 36 regained 14% of their weight over the next 52 weeks, while those continued on tirzepatide lost an additional 5.5%.<\/p>\n Both drugs have been on market less than 10 years, so very long-term (15-20 year) data isn’t available yet. The expectation is lifelong use for most patients with obesity, similar to other chronic disease medications.<\/p>\n The choice depends on what you’re optimizing for.<\/strong> For pure weight loss, tirzepatide wins. For cardiovascular outcomes and kidney protection, semaglutide has the stronger evidence base in 2026. For sleep apnea, tirzepatide has the only FDA-approved label.<\/p>\n For patients with no specific comorbidity driving the decision, raw efficacy data favors tirzepatide. For patients with established cardiovascular disease, kidney disease, or a strong family history of CV events, semaglutide’s outcome data is reassuring. For patients who can’t tolerate one, the other is worth trying.<\/p>\n TrimRx’s free assessment quiz screens eligibility for both compounded semaglutide and compounded tirzepatide and matches patients to a personalized treatment plan.<\/p>\n Bottom line: Brand Wegovy lists at $1,349\/month, brand Zepbound at $1,086\/month; compounded versions through TrimRx run $200 to $500\/month<\/p>\n Yes, switching is common and clinically appropriate when weight loss plateaus on semaglutide or when tirzepatide’s stronger effect is preferred. Most clinicians start tirzepatide at a dose slightly higher than the starting dose (often 5 mg instead of 2.5 mg) if the patient was at a high semaglutide dose, then titrate from there.<\/p>\n The safety profiles are very similar. Both have the same boxed warning (medullary thyroid C-cell tumors based on rodent data) and the same major side effects (GI). SURMOUNT-5 head-to-head showed comparable serious adverse event rates. Neither has emerged as clearly safer than the other in the published data.<\/p>\n Tirzepatide activates both GLP-1 and GIP receptors. The combined receptor activation appears to produce greater weight loss than GLP-1 activation alone. The exact mechanism by which GIP contributes is still being studied, but the clinical effect is consistent across trials.<\/p>\n Insurance coverage varies. Many plans require step therapy (trying one before the other). Some plans cover only the diabetes indications (Ozempic, Mounjaro) and not the obesity brands (Wegovy, Zepbound). Coverage shifts annually as formularies update.<\/p>\n Compounded tirzepatide containing the same active ingredient at the same dose should produce similar clinical effects, though it isn’t FDA-approved or tested in head-to-head trials. Quality varies by pharmacy. The FDA removed tirzepatide from the shortage list in late 2024, restricting which patients can legally receive compounded versions.<\/p>\n Some patients do, especially those with substantial weight to lose or those with diabetes plus obesity. Others prefer to start with semaglutide because of its longer track record and cardiovascular evidence base. Either is a reasonable first choice for most patients without a specific contraindication.<\/p>\n Both drugs produce some appetite reduction within the first 1 to 2 weeks at starter doses. Meaningful weight loss typically becomes visible by weeks 4 to 8. Peak weight loss happens between months 6 and 18 depending on the dose escalation and the patient’s response curve.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" For three years semaglutide was the standard. Wegovy hit the market in 2021 with the STEP 1 trial showing 14.9% mean weight loss at 68 weeks.<\/p>\n","protected":false},"author":11,"featured_media":93334,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Semaglutide vs Tirzepatide: The Ultimate Head-to-Head Guide","_yoast_wpseo_metadesc":"For three years semaglutide was the standard. Wegovy hit the market in 2021 with the STEP 1 trial showing 14.9% mean weight loss at 68 weeks.","_yoast_wpseo_focuskw":"semaglutide tirzepatide","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[21,46,52],"class_list":["post-90613","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic","tag-comparisons","tag-semaglutide","tag-tirzepatide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90613"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90613\/revisions"}],"predecessor-version":[{"id":91858,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90613\/revisions\/91858"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93334"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Which Produces More Weight Loss?<\/h2>\n
What About Cardiovascular Outcomes?<\/h2>\n
What About Kidney Outcomes?<\/h2>\n
What About Sleep Apnea?<\/h2>\n
What About Diabetes Control?<\/h2>\n
Side Effect Profile Comparison<\/h2>\n
What Does Each Cost?<\/h2>\n
Which Titrates Faster?<\/h2>\n
How Long Can You Stay on Each?<\/h2>\n
Which Is Right for You?<\/h2>\n
FAQ<\/h2>\n
Can I Switch From Semaglutide to Tirzepatide?<\/h3>\n
Is One Safer Than the Other?<\/h3>\n
Why Is Tirzepatide More Effective?<\/h3>\n
Will My Insurance Cover One but Not the Other?<\/h3>\n
Is Compounded Tirzepatide as Effective as Brand Zepbound?<\/h3>\n
Should I Start with Tirzepatide If It’s Stronger?<\/h3>\n
How Long Does Each Take to Start Working?<\/h3>\n